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ABSTRACT 
Gastro-oesophageal reflux disease (GORD), with heartburn and acid regurgitation as 
main symptoms, is a common disease with increasing prevalence. GORD is 
associated with oesophageal adenocarcinoma, a cancer with demanding treatment and 
yet poor prognosis. GORD is typically managed with pharmacological treatment, 
mainly using proton pump inhibitors, or through laparoscopic antireflux surgery. The 
aim of this thesis was to evaluate outcomes of antireflux surgery, i.e. safety, 
effectiveness and prevention of oesophageal adenocarcinoma. 
Study I and II were nationwide Swedish cohort studies based on data from the 
Patient Registry, Causes of Death Registry, Registry of the Total Population (in  
study I only), and the Swedish Prescribed Drug Registry (in study II only). Study I 
assessed safety aspects with focus on the risk of mortality, reoperation and prolonged 
hospital stay among patients of working age who underwent primary laparoscopic 
antireflux surgery for GORD. In addition, it provided descriptive data regarding trends 
and comorbidities among patients who had undergone such surgery. The study found 
low risks of mortality (0.08%) and reoperation (0.4%) within 90 days of surgery. 
Patients of female sex, and older age and with more comorbidities had an increased 
risk of prolonged hospital stay. Generally, the number of patients who underwent 
antireflux surgery in Sweden decreased substantially during the period, while the 
proportion with severe comorbidities among the operated patients increased over time. 
Study II assessed the risk of recurrence of reflux symptoms following primary 
laparoscopic antireflux surgery for GORD, using reoperation or prescribed 
medications against reflux (exceeding six months of treatment) as the measures of this 
outcome. The reflux recurrence rate was 17.7% during the median follow-up of 5.6 
years, and the majority of patients (83.6%) had medical treatment. Female sex, older 
age, and comorbidity were associated with an increased reflux recurrence, but hospital 
volume was not.  
Study III was a systematic review and meta-analysis assessing if oesophageal 
adenocarcinoma can be prevented by antireflux surgery. No clear differences in risk 
were found when comparing surgery with medication, and the risk of oesophageal 
adenocarcinoma remained elevated following antireflux surgery compared to the 
general background population. Study IV was a Nordic cohort study, based on 
nationwide registries from Denmark, Finland, Iceland, Norway, and Sweden, 
including patients with GORD. The risk of oesophageal adenocarcinoma was initially 
high, but decreased over time both following antireflux surgery and presumed medical 
therapy to a risk in line with that of the general background population after 15 years. 
The risk of oesophageal adenocarcinoma was similar when directly comparing 
medical and surgical therapy. 
In conclusion, laparoscopic antireflux surgery can be considered a safe and effective 
treatment option of GORD which is potentially underused in clinical practice, 
especially among young and otherwise healthy individuals who might otherwise need 
lifelong medical treatment. Effective treatment of GORD seems to reduce the risk of 
oesophageal adenocarcinoma.  
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1 INTRODUCTION 
Long-standing gastro-oesophageal reflux disease (GORD), with the main symptoms 
heartburn and acid regurgitation, affects approximately 10 to 20% of the adult 
population and has become increasingly common during the last decades.1,2 Besides 
the symptoms of GORD which can reduce quality of life substantially, GORD also 
drastically increases the relative risk of developing oesophageal adenocarcinoma, a 
cancer characterised by increasing incidence, demanding treatment and poor 
prognosis.  
Patient with GORD are primarily treated with medical therapy. An alternative 
treatment option is surgery, specifically laparoscopic antireflux surgery, which is what 
this thesis focuses on.  
Included in the thesis are three original studies based on data from nationwide 
registries as well as one systematic review and meta-analysis. The first two studies 
examine different outcomes of laparoscopic antireflux surgery, including efficiency 
and safety. The latter two studies, the meta-analysis and one original study, aim to 
clarify whether antireflux surgery prevents oesophageal adenocarcinoma. 
 
  
 2 
2 BACKGROUND 
2.1 THE OESOPHAGUS: ANATOMY AND HISTOLOGY 
The oesophagus is a muscular tube connecting the pharynx to the stomach, its length 
is approximately 25 cm and the average width is 2 cm.3 The oesophagus functions as a 
conduit that transports solids and liquids from the mouth to the stomach through 
peristalsis, but it also enables regurgitation of stomach contents and air through the 
mouth.3 The gross anatomy of the oesophagus in relation to the stomach and the 
directly adjacent abdominal organs is shown in Figure 1. The oesophagus follows the 
curvature of the vertebral column, and passes through the hiatus of the diaphragm at 
approximately the height of the 10th thoracic vertebrae, and then deviates to the left 
and enters the stomach slightly to the left of the midline at the height of the 11th 
thoracic vertebrae.3  
 
Figure 1. Anatomy of the oesophagus passing behind the left lobe of the liver and entering  
the stomach. The drawing was made by the author. 
  3 
The oesophagus receives its arterial blood supply through branches from the inferior 
thyroid artery (cervical portion), oesophageal and bronchial branches of the thoracic 
part of the aorta (thoracic portion), and ascending oesophageal branches of the left 
phrenic and left gastric artery (abdominal portion).4 The venous blood is drained 
through the inferior thyroid vein (cervical portion), azygos, hemiazygos, intercostal 
and bronchial veins (thoracic portion), and the left gastric vein (abdominal portion).4 
Histologically, the oesophagus consists of four main layers; the mucosa, submucosa, 
muscularis propria and adventitia. The mucosa can be subdivided into three distinct 
layers; the epithelium, which normally is native non-keratinized stratified squamous 
epithelium, the lamina propria, consisting of connective tissue, and the muscularis 
mucosae, which consists of longitudinally arranged smooth muscle bundles.5 The 
gastro-oesophageal junction is defined by the start of the longitudinal folds of the 
proximal stomach. Histologically the junction is defined by where the mucosa 
changes from oesophageal to gastric epithelium, known as the Z-line, unless there is 
columnar metaplasia, i.e. Barrett´s oesophagus, which distorts the Z-line.3 The 
submucosa consists of loose connective tissue, mainly containing arteries, veins, 
lymphatic vessels and nodes and nerves.5 The next layer is, as previously mentioned, 
the muscularis propria, consisting of two muscle layers: the inner circular and the 
outer longitudinal layer, and finally the adventitia is mainly constituted by connective 
tissue.5 In contrast to the major part of the gastrointestinal system, the oesophagus has 
no serosa.5  
2.2 GASTRO-OESOPHAGEAL REFLUX DISEASE 
GORD is defined as a “condition that develops when the reflux of duodeno-gastric 
contents causes troublesome symptoms and/or complications”, according to the 
Montreal definition.6 GORD occurs when reflux reaches the oesophagus and causes 
reduced quality of life, reflux oesophagitis or long-term complications, i.e. dysphagia, 
strictures, Barrett’s oesophagus and oesophageal adenocarcinoma.6,7 The most 
common symptoms of GORD are heartburn and regurgitation of stomach contents 
into the oropharynx, and less common symptoms include chest pain, nausea, 
dysphagia, cough and hoarseness.8 The majority of patients will remain with a similar 
grade of severity of GORD over time.9,10 The prevalence of weekly or severe GORD 
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is assessed to be 10 to 20% in the western world, however, the prevalence has almost 
doubled since the mid-1990s.2 GORD is primarily considered a clinical diagnosis, 
mainly relying on the clinical presentation and symptoms, and empirical treatment 
with a proton pump inhibitor (PPI) without endoscopic evaluation can help confirm 
the diagnosis.11,12 A mechanism for developing GORD is the development of a hiatus 
hernia, in which a part of the stomach protrudes or migrates through the diaphragm 
into the thoracic cavity, thereby, decreasing the integrity of the lower oesophageal 
sphincter.13 Hiatal hernias have been reported to be found in approximately 80-90% of 
GORD patients.14 There are several environmental risk factors for GORD, and the two 
most well established are obesity and tobacco smoking. Obesity, and more 
specifically abdominal obesity, has been determined to increase the risk of GORD 
symptoms, but also complications of GORD such as oesophagitis, Barrett’s 
oesophagus and oesophageal adenocarcinoma.15,16 Weight loss can increase the 
chances of reduction of GORD symptoms.17 Tobacco smoking has been found to be 
weakly associated with symptoms of GORD, and smoking is also associated with an 
increased risk of Barrett’s oesophagus and oesophageal adenocarcinoma.15,18-21 Some 
studies have found an association between consumption of alcohol and GORD 
symptoms, although causality between alcohol and new onset of GORD have not been 
found in recent reviews.15,22-24 
2.3 TREATMENT OF GASTRO-OESOPHAGEAL REFLUX DISEASE 
2.3.1 Pharmacological treatment 
2.3.1.1 Proton pump inhibitors 
The most commonly prescribed, and most effective, pharmacological treatment of 
GORD is medication using PPI, which irreversibly inhibit H+/K+ ATPase in the 
parietal cells in the gastric epithelium, thus preventing transportation of H+ across the 
cell wall suppressing the production of acid in the stomach.25 Thereby, PPI does not 
reduce the presence of reflux in itself, but rather reduces the acidity of the refluxate, 
alleviating symptoms.26 Treatment with PPI diminishes heartburn in 37 to 61% of 
patients without oesophagitis, but among patients with oesophagitis, PPI leads to 
healing of oesophagitis in 72 to 83%, and relief of heartburn in 56 to 77% of the 
  5 
patients.27-31 Initial treatment with PPI is once daily, and if sufficient relief of GORD 
is not achieved, the dose can be increased to twice daily.32 PPI use has been shown to 
be superior to treatment with the second most common pharmacological treatment, 
histamine2 receptor antagonists, both regarding healing of oesophagitis and relieving 
symptoms of GORD.29,30 Current clinical guidelines recommend treatment with PPI in 
the lowest tolerable daily dose as the main treatment for GORD.33 Attempts should be 
made to reduce and stop the treatment, however, patients who do not tolerate this 
might need long-term, sometimes even life-long, treatment.33 There are some 
indications from observational studies that long-term treatment with PPI might lead to 
side-effects, such as an increased risk of hip fractures, Clostridium difficile-associated 
diarrhoea and community-acquired pneumonia, although the evidence is not 
consistent.11,34-37 Some studies have also suggested that PPI medication increases the 
future risk of gastric cancer.38,39  
2.3.1.2 Histamine2 receptor antagonists 
Histamine2 receptor antagonists were introduced in the late 1970’s and these are 
competitive antagonist against histamine receptors in the parietal cells of the stomach, 
reducing the gastric acidity. Treatment with histamine2 receptor antagonists 
diminishes heartburn in 48 to 56% of patients, and leads to healing of oesophagitis in 
approximately 41% of patients.27,28,30,31,40 Histamine2 receptor antagonists are 
currently mainly used as a step-down treatment when attempting to stop treatment 
with PPI.11 Histamine2 receptor antagonists can also be used to enhance the 
effectiveness and symptom relief achieved with PPI use.41 
2.3.2 Antireflux surgery 
Antireflux surgery is considered a permanent treatment of severe and well-
documented GORD. It is generally considered in three main clinical settings: instead 
of medication when long-term medication is necessary, against persistent symptoms 
or damage to the oesophageal mucosa despite high dose medical treatment, or when 
there is confirmed disruption at the gastro-oesophageal junction, such as large hiatal 
hernias.11 The main principle of antireflux surgery (also called fundoplication) is to 
wrap the fundus of the stomach around the distal oesophagus, a surgical method that 
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was first described by Rudolph Nissen in 1956, shown in Figure 2.42 The original 
antireflux surgery as described by Nissen includes wrapping the fundus completely, 
360 degrees, around the distal oesophagus, hence reinforcing the lower oesophageal 
sphincter. This has been shown to give excellent control of GORD.43  
 
Figure 2. The anatomic alterations achieved through antireflux surgery, in frames 1 and 3 the 
diaphragm is also seen. Drawing by the author. 
However, studies have also shown that there is an increased risk of dysphagia and 
gas-related symptoms following a complete Nissen fundoplication, and due to this, 
alternative methods of antireflux surgery have been developed. The most common are 
the Toupet posterior partial fundoplication, where the fundus is partially wrapped 200-
270 degrees posterior of the oesophagus and sutured (first described by André Toupet 
1963) and the Dor anterior partial fundoplication, where the fundus is partially 
wrapped 180 degrees anterior of the oesophagus and sutured (first described by 
Jacques Dor 1962).44,45 The introduction of laparoscopic approaches in the 1990’s has 
lowered the operative morbidity rate, the length of the postoperative stay as well as 
the length of sick leave.46 Laparoscopic techniques have not been found to improve 
the results regarding recurrence of gastro-oesophageal reflux, dysphagia, bloating or 
reoperation, compared to open surgical techniques.46 Two recent meta-analyses 
included randomized controlled trials comparing complete laparoscopic antireflux 
surgery ad modum Nissen to either laparoscopic partial antireflux surgery ad modum 
Toupet or laparoscopic partial antireflux surgery ad modum Dor.47,48 The studies 
showed that reflux control was equivalent following all these procedures, but with 
significantly lower rate of postoperative dysphagia and lower rate of gas-related 
symptoms following both Toupet and Dor fundoplications compared to Nissen 
fundoplication.47,48 Despite effective initial results, some patients need a redo 
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antireflux surgery due to recurrence of reflux. A population-based Danish study 
concluded that 113 of 2,465 patients (4.6%) required a reoperation following primary 
antireflux surgery, and a large study including 13,050 patients in the United States 
concluded that 5.2% required reoperation within five years and 6.9% within ten years 
of the primary surgery.49,50 A recent Cochrane review including four randomized 
controlled trials and 1,232 patients concluded that the postoperative results following 
laparoscopic antireflux surgery were better compared to medical treatment using PPI, 
both regarding quality of life in the short and long term, but also regarding symptoms 
of reflux, heartburn and bloating.43 Earlier studies evaluating antireflux surgery in a 
long-term setting have determined that a majority of patients (60-90%) were free of 
symptoms or did not require antisecretory medication at 5-17 years of follow-up.51-53 
Although the risk of complications was low, and mortality rare, these risks are still 
present in a surgical setting compared to medical therapy.43 A recent review 
concluded that based on these results and the risks associated with surgery, medical 
therapy should be recommended as the first-line treatment for severe GORD.54 
However, among young and healthy individuals with severe symptoms, where very 
long-term medical treatment otherwise would be needed, surgery should be 
considered.54  
2.4 COMPLICATIONS TO GASTRO-OESOPHAGEAL REFLUX 
DISEASE 
2.4.1 Barrett’s oesophagus 
Following long-term GORD with chronic acid exposure and tissue injury to the 
epithelium of the oesophagus, the epithelium can heal with a conversion of the cell 
type, metaplasia, causing squamous cells of the oesophageal lining to be replaced by 
mucus-secreting columnar cells.55,56 This epithelium replacing the squamous cells of 
the oesophagus is referred to as Barrett’s oesophagus and is characterised by 
intestinal-like specialised columnar cells, and although it is generally more resistant to 
acidic reflux, it is also one of the major and most well established predisposing factors 
for the development of oesophageal adenocarcinoma.57 Barrett’s oesophagus was first 
described by the thoracic surgeon Norman Barrett in 1950, and the causality between 
gastro-oesophageal reflux and Barrett’s oesophagus was determined a few years 
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later.58,59 The symptoms of Barrett’s oesophagus are similar to the symptoms of 
GORD, hence there are no specific symptoms to distinguish Barrett’s oesophagus 
from GORD, and endoscopy with biopsies with histopathological confirmation is 
necessary to diagnose Barrett’s oesophagus.32 Recent studies report a specifically 
increased risk of Barrett’s oesophagus among overweight Caucasian men aged over 
50 with long term history of GORD.60 Larger studies that have attempted to estimate 
the prevalence of Barrett’s oesophagus have determined it to be approximately 1.3-
1.6% in the adult western population, although some studies have estimated this 
number to be as high as 5.6%.61-63 It is still uncertain how high the risk of oesophageal 
adenocarcinoma is among patients with Barrett’s oesophagus, but recent large-scale 
studies estimate that the rate of progression to oesophageal adenocarcinoma ranges 
between 0.1 to 0.3% per year in the general population.64,65 Patients with known 
Barrett’s oesophagus are often monitored with surveillance endoscopy in order to 
detect dysplasia and early cancers, leading to better survival if cancer occurs.57,60,66,67 
Which patients with Barrett’s oesophagus to survey is a matter of debate. A recent 
consensus statement concluded that patients with Barrett’s oesophagus without signs 
of dysplasia should only be surveyed if they are high-risk patients, i.e. men above 60 
years of age with symptoms.60 Further, patients with low-grade dysplasia should be 
monitored closely, and if the low-grade dysplasia affects a long segment, is 
multifocal, and persistent, ablative therapy or endoscopic resection should be 
performed.60 High-grade dysplasia should be treated using endoscopic or surgical 
resection, and in some cases radiofrequency ablation can also be considered.66 
2.4.2 Oesophageal adenocarcinoma 
Oesophageal adenocarcinoma is a malignancy with cellular origin from glandular 
cells in Barrett’s oesophagus. Adenocarcinoma of the oesophagus and gastro-
oesophageal junction have been found to be similar regarding pathology and risk 
factors, and are therefore considered to be the same clinical entity as of the 7th edition 
of the American Joint Committee on Cancer staging manual.68,69 The incidence of 
oesophageal adenocarcinoma has increased drastically during the last four decades, 
from being a rare histological subtype of oesophageal cancer, to being the most 
common histological subtype of oesophageal cancer in many western countries.70,71 
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This increase seems to have started in the 1970’s and 1980’s in many countries, 
including Sweden, and is continuing still today, as shown in Figure 3.70,72 There is a 
strong male predominance of oesophageal adenocarcinoma, which remains 
unexplained and has remained during the period of increasing incidence. The average 
male-to-female ratio is approximately 6:1 in western countries, including Sweden. 
 
Figure 3. Cases of oesophageal adenocarcinoma per 100,000 adult men and women in Sweden 
between 1970 and 2016.73 
2.4.2.1 Symptomatology and diagnosis of oesophageal adenocarcinoma  
The most common presenting symptoms of oesophageal adenocarcinoma are 
progressive dysphagia, developing over a few months, as well as weight loss, fatigue 
and anaemia.74 Due to often diffuse or non-present initial symptoms of the tumour, the 
noticeable symptoms often occur late when the tumour has already started to invade 
the muscle layers of the oesophagus, and by that time have often metastasised to 
lymph nodes or distant organs. Therefore, only approximately 25% of the patients 
present with a localised tumour at the time of diagnosis.75 Similar to the diagnosis of 
Barrett’s oesophagus, upper endoscopy including biopsies for pathological assessment 
is the gold standard for diagnosing oesophageal adenocarcinoma. Despite that patients 
with Barrett’s oesophagus are a high risk population, less than 15% of all cases of 
oesophageal adenocarcinoma are discovered within surveillance programs, mainly 
because most individuals with Barrett’s are never recognised.76,77  
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2.4.2.2 Treatment of oesophageal adenocarcinoma 
Due to the fact that oesophageal adenocarcinoma is most commonly discovered at a 
late stage, one of the most important aspects is to identify patients that might be 
possible to treat with a curative intent. Following endoscopic evaluation, histological 
grading, and imaging assessment, an accurate staging can be achieved. For very early 
and superficial adenocarcinomas (T1a), endoscopic resection or endoscopic ablation is 
sometimes possible.74 For locally advanced adenocarcinomas, meaning that the 
tumour is invading deeper tissues of the oesophagus but without lymphatic spread or 
distant metastases, surgical treatment is standard therapy. The most common 
procedure to be performed is oesophagectomy, either with a gastric pull-up, where the 
mobilised stomach is formed to function as an oesophagus, or with a colonic 
interposition, where the mobilised colon is replacing the resected oesophagus.74 The 
surgical treatment is often accompanied by neoadjuvant chemotherapy or 
chemoradiotherapy, which has been shown to increase overall survival and rate of 
radical resection when comparing to surgical therapy alone.78,79 It remains unclear 
however, whether neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy is 
most beneficial regarding long-term survival.79 Despite recent research regarding 
treatment of oesophageal adenocarcinoma, the prognosis remains very poor. The 
overall five-year survival was approximately 5% in 1975, and recent studies have 
estimated the overall five-year survival to approximately 15-20%.75,80 Patients with 
unresectable or metastatic disease are often treated with palliative chemotherapy or 
chemoradiotherapy.74 In a palliative setting, endoscopic management and treatment of 
dysphagia can be important, mainly using stenting of the oesophagus.74 
2.4.2.3 Risk factors of oesophageal adenocarcinoma 
During the late 1990’s, it was established that GORD is a main risk factor for 
oesophageal adenocarcinoma.81 A meta-analysis including five studies concluded that 
the odds ratio of developing oesophageal adenocarcinoma was nearly five times 
higher among individuals suffering from weekly symptoms of gastro-oesophageal 
reflux (heartburn or regurgitation) compared to those with less frequent or no reflux 
symptoms (odds ratio 4.92, 95% confidence interval [CI] 3.90-6.22), and increased 
more than seven times for individuals experiencing reflux symptoms on a daily basis 
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(odds ratio 7.40, 95% CI 4.94-11.1).82 Increased body mass index is also associated 
with an increased risk of oesophageal adenocarcinoma, and a recent meta-analysis of 
22 studies concluded that compared to individuals with normal body mass index, the 
risk ratio was 1.71 (95% CI 1.50-1.96) of developing oesophageal adenocarcinoma if 
the body mass index is 25-30, and 2.34 (95% CI 1.95-2.81) if ≥30.83 A pooled 
analysis of 12 observational studies comparing individuals with body mass index 
below 25 to those with a body mass index ≥40, the odds ratio of oesophageal 
adenocarcinoma was 3.65 (95% CI 2.50-5.34).84 Based on the available literature, a 
linear association between increased body mass index and risk of oesophageal 
adenocarcinoma can be seen. A meta-analysis (including 3 cohort and 3 case-control 
studies) determined that predominantly abdominal or visceral adiposity increased the 
risk of oesophageal adenocarcinoma significantly, independent of body mass index.16 
Finally, tobacco smoking is associated with a moderately increased risk of developing 
oesophageal adenocarcinoma. A meta-analysis (including 33 studies) found a risk 
ratio of 1.76 (95% CI 1.54-2.01), and a pooled analysis (including 10 population-
based studies) comparing ever and never smokers found an odds ratio of 2.08 (95% CI 
1.83-2.37).21,85 
2.4.2.4 Prevention of oesophageal adenocarcinoma 
A recent meta-analysis, including seven observational studies, concluded that 
medication with PPI in patients with Barrett’s oesophagus decreased the risk of 
developing oesophageal adenocarcinoma or high-grade dysplasia compared to non-
users (odds ratio 0.29, 95% CI 0.12-0.79).86 This is however debated, and a 
population-based Danish case-control study found an increased risk of high-grade 
dysplasia or oesophageal adenocarcinoma despite medication with PPI, both among 
low- and high-adherence users (relative risk of 2.2, 95% CI 0.7-6.7, and 3.4, 95% CI 
1.1-10.5, respectively).87 However, after adding the Danish study to the meta-analysis 
previously referred to, an overall protective effect remained.88 Despite the association 
between body mass index and oesophageal adenocarcinoma, it is unclear whether 
weight loss prevents the development of oesophageal adenocarcinoma. This is 
partially due to unpredictable variations in weight over time and the lack of long-
lasting weight loss among obese individuals, hence making it unreliable to use as an 
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exposure in large cohort studies. Obesity surgery can be regarded a human model to 
assess if weight loss reduces the risk of oesophageal adenocarcinoma, based on the 
stable and drastic long-term reduction in weight starting from a specific date.89,90 A 
systematic review including 28 studies identified only eleven cases of oesophageal 
adenocarcinoma following obesity surgery, which made analyses impossible.91 A 
recent population-based Swedish cohort study including 34,437 individuals who 
underwent obesity surgery identified eight cases of oesophageal adenocarcinoma, and 
no difference in risk of oesophageal adenocarcinoma was seen compared to obese 
patients that did not undergo obesity surgery.92 Regarding tobacco smoking, a pooled 
analysis of ten studies showed that smoking cessation reduced the risk of oesophageal 
adenocarcinoma over time compared to current smokers.21 Smoking cessation for less 
than 10 years was associated with an odds ratio of 0.82 (95% CI 0.60-1.13) and the 
corresponding number after more than 10 years of cessation was 0.71 (95% CI 0.56-
0.89), however, the risk did not decrease to the level of never smokers.21   
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3 AIMS  
3.1 OVERALL AIM OF THE THESIS 
To estimate outcomes of antireflux surgery regarding safety, effectiveness and 
prevention of oesophageal adenocarcinoma. 
3.2 SPECIFIC AIMS OF THE INCLUDED STUDIES  
 To assess the risk of complications and mortality following antireflux surgery. 
 To determine the risk of recurrence of gastro-oesophageal reflux following 
antireflux surgery. 
 To estimate the risk of oesophageal adenocarcinoma following antireflux 
surgery in the published literature. 
 To clarify the risk of developing oesophageal adenocarcinoma over time 
following antireflux surgery in a multinational cohort. 
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4 MATERIAL AND METHODS 
4.1 OVERVIEW 
An overview of the methods used in studies I-IV is presented in Table 1. 
Table 1. Methods in study I-IV. 
 Study I Study II Study III Study IV 
Study design Population-based 
cohort study 
Population-based 
cohort study 
Systematic review 
and meta-analysis 
Population-based 
cohort study 
Data sources Swedish 
nationwide 
registries: Patient 
Registry, Causes of 
Death Registry, 
Registry of the 
Total Population 
Swedish nationwide 
registries: Patient 
Registry, Causes of 
Death Registry, 
Prescribed Drug 
Registry 
PubMed/MedLine, 
Web of Science, 
Cochrane 
databases 
Nordic nationwide 
registries: Patient 
Registries, Cancer 
Registries, Causes 
of Death Registries 
and the Swedish 
Prescribed Drug 
Registry 
Study period 1997-2013 2005-2014 -2014 1964-2014 
Inclusion Patients (age 18-65) 
undergoing primary 
laparoscopic 
antireflux surgery 
due to gastro-
oesophageal reflux 
disease 
Patients (age >18) 
undergoing primary 
laparoscopic 
antireflux surgery 
due to gastro-
oesophageal reflux 
disease 
Patients with 
gastro-oesophageal 
reflux disease 
undergoing 
antireflux surgery 
or receiving 
medication 
Patients (age >18) 
undergoing 
antireflux surgery 
due to gastro-
oesophageal reflux 
disease 
Outcome Mortality (within 
30 and 90 days), 
reoperation (within 
90 days) and 
prolonged hospital 
stay 
Recurrence of reflux 
(prescribed 
medication >6 
months or 
reoperation) 
Oesophageal 
adenocarcinoma 
Oesophageal 
adenocarcinoma 
Cohort members 8,947 2,655 - 942,906 
Main statistical 
analysis 
Multivariable 
logistic regression 
Multivariable Cox 
regression 
Fixed-effects 
Poisson meta-
analysis 
Standardized 
incidence ratio and 
multivariable Cox 
regression 
Co-variables Age, sex, year of 
surgery, co-
morbidities 
(Charlson co-
morbidity score) 
Age, sex, year of 
surgery, co-
morbidities 
(Charlson co-
morbidity score), 
hospital volume 
 Standardized 
incidence ratio: 
Age, sex, calendar-
period 
Multivariable Cox 
regression: Age, 
sex, calendar 
period, chronic 
obstructive 
pulmonary disease, 
and obesity or 
diabetes  
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4.2 DATA SOURCES 
4.2.1 The Nordic Patient Registries 
All patient registries in the Nordic countries include discharge diagnoses from the in-
patient care, and in many cases specialised out-patient care, in each country, and 
thereby provide longitudinal registration of diagnoses. The diagnoses are registered 
using the International Classification of Diseases, as well as codes for surgical 
procedures. Since the late 1990s, the Nordic Medico-Statistical Committee 
(NOMESCO) Classification of Surgical Procedures is used for coding of surgeries 
and interventions, which makes it possible to distinguish open and laparoscopic 
procedures.93 The year of initiation of the patient registries varies in the different 
countries. However, due to the mainly publicly funded healthcare in the Nordic 
countries, the completeness of the registries is high.94,95 The Danish Patient Registry 
was founded in 1977 by the Danish Health and Medicines Authority, and nationwide 
coverage was reached in 1978.96 Since the initiation, somatic inpatient care was 
included, and later psychiatric and somatic in- and outpatient care was added.96 A 
recent systematic review including 114 studies concluded that the positive predictive 
value as a measurement of the validity ranged widely (between 15-100%).97 The 
Finnish Patient Registry was founded in 1967 by the National Institute for Health and 
Welfare with nationwide coverage since its initiation. In 1969 the personal 
identification number was added, enabling linkage to other registries.98 The registry 
was renamed to the Finnish Care Register for Health Care in 1994, after which it also 
included specialised outpatient care and day surgery, and not only somatic inpatient 
care.98,99 The Icelandic Patient Registry was founded in 1999 and is managed by the 
Icelandic Directorate of Health, and data is continuously collected from the 
hospitals.100 The Norwegian Patient Registry was founded in 1997, and is managed by 
the Norwegian Directorate of Health.101 Both the Icelandic and Norwegian Patient 
registries have been nationwide since their initiation. The Swedish Patient Registry 
was founded in 1964, and reached nationwide completeness regarding inpatient 
healthcare in 1987, and the validity has been determined to range between 85-95% for 
most diagnoses.102  
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4.2.2 The Nordic Cancer Registries 
The Cancer Registries in the Nordic Countries include the date and anatomical and 
histological codes of all tumours in each country since the year of initiation. Other 
variables included in the registries vary slightly between the different countries, but 
generally there are variables corresponding to the geographical localization of the 
hospital, how the diagnosis was made, whether the tumour was benign or malignant, 
and if the patient had had a previous tumour. The percentage of cases that are 
microscopically verified varies between countries, ranging from 93 to 98%.103 The 
Danish Cancer Registry was founded in 1942, and registration has been mandatory 
since 1987.104 The Finnish Cancer Registry was founded in 1953, with mandatory 
registration since 1961.105 The Icelandic Cancer Registry was founded in 1954, and 
registration has been mandatory since its initiation.106 The Norwegian Cancer Registry 
was founded in 1951, and registration has been mandatory since its initiation.107 The 
Swedish Cancer Registry was founded in 1958, and registration has been mandatory 
since its initiation.108  
4.2.3 The Nordic Causes of Death Registries 
The Causes of Death Registries in the Nordic countries share a similar structure. The 
main variables used in this thesis are date of death, main cause of death and 
underlying causes of death. These registries in all the Nordic countries have been 
nationwide and had mandatory registration since their initiation. The years of 
initiation were 1970 (Denmark), 1969 (Finland), 1952 (Iceland), 1951 (Norway), and 
1952 (Sweden).95 The Swedish Causes of Death Registry has been validated, and the 
completeness has been determined to be high regarding date of death (100%) and 
underlying cause of death (96%), and the agreement between death certificates and 
manually assessed causes of death has been compared and determined to be high.109-
111 
4.2.4 The Swedish Prescribed Drug Registry 
The Swedish Prescribed Drug Registry was founded in 1st of July 2005 and contains 
data on all prescribed and dispensed medications in Sweden from this date. According 
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to Swedish law, all prescriptions in Sweden have to be reported, and are filed 
electronically into the registry, which contributes to its nearly 100% coverage.112  
4.2.5 The Swedish Registry of the Total Population 
The population statistics in Sweden was initiated in 1749 and was centralised under 
the Swedish tax agency in 1962, but managed by Statistics Sweden.113 The registry 
contains for example data regarding birth, death, emigration, immigration, marriage, 
country of birth, sex, and citizenship. It is estimated that the reporting within 30 days 
is 100% regarding birth and death, 95% regarding immigration, and 91% regarding 
emigration, and an even higher reporting rate over time.114 
4.3 SUBJECTS AND METHODS 
4.3.1 Study I 
4.3.1.1 Design 
Nationwide Swedish population-based cohort study. 
4.3.1.2 The cohort and the follow-up 
The cohort included all patients in Sweden with a diagnosis of GORD who underwent 
primary laparoscopic antireflux surgery, identified in the Swedish Patient Registry 
from the NOMESCO code JBC01 (Laparoscopic surgery against gastro-oesophageal 
reflux). The cohort was restricted to patients of working age, defined as age 18-65 
years. Because the study only included patients who had undergone antireflux surgery 
using a laparoscopic approach, the study period was restricted to range from 1997 
onwards, which was the year that the NOMESCO was introduced and separate codes 
for open and laparoscopic approaches became available. The entire Patient Registry 
since its initiation was searched for diagnoses representing GORD. The diagnoses 
used to identify these patients were GORD, heartburn, hiatal hernia, oesophagitis and 
Barrett’s oesophagus. The primary outcome of the study was all-cause and surgery-
related 30- and 90-day mortality. Secondary outcomes were reoperation within 90 
days and prolonged length of postoperative hospital stay (four days or more). 
Reoperations were identified with any NOMESCO code beginning with JW 
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(Reoperation in the gastrointestinal tract). The Swedish Causes of Death Registry was 
used to identify deaths and underlying causes, and the Swedish Registry of the Total 
Population was used to calculate the rate of surgery in the entire country. Based on the 
data in the Patient Registry, the Charlson Co-morbidity Index score was calculated for 
all patients included in the cohort.115-119  
4.3.1.3 Statistical methods 
All patients who died or underwent reoperation within the cohort were identified and 
descriptive data of the absolute risk of death within 30 and 90 days following 
antireflux surgery were retrieved. Due to the low number of deaths, no further 
analyses could be conducted on this group. Patients undergoing reoperation or 
requiring prolonged postoperative hospital stay were further analysed using a 
multivariable logistic regression model determining the odds ratios and 95% CI of 
reoperation within 90 days of surgery as well as prolonged hospital stay. The 
regression models were adjusted for age, sex, year of surgery (1997-2002, 2003-2008 
or 2009-2013) and co-morbidities (Charlson score 0, 1 or ≥2). Additionally, a spline 
was fitted modelling the changes in odds ratio for prolonged hospital stay during the 
study period (as a continuous variable). 
4.3.2 Study II 
4.3.2.1 Design 
Nationwide Swedish population-based cohort study. 
4.3.2.2 The cohort and the follow-up 
This cohort was collected in a similar way as the cohort in Study I. Based on the 
Swedish Patient Registry, all patients with GORD (or an associated disorder) who 
subsequently underwent primary laparoscopic antireflux surgery were identified. The 
codes used to identify patients with GORD were the same as those in Study I. The 
patients were linked to the Swedish Prescribed Drug Registry, and due to the year of 
initiation of the Prescribed Drug Registry, the cohort was restricted to include patients 
who underwent primary laparoscopic antireflux surgery between 2005 and 2014. To 
ensure that only primary surgeries were included, all patients who underwent 
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antireflux surgery (open or laparoscopic) before 2005 were excluded by using the 
surgical code 4272 before the year 1997, and the codes JBC00, JBC01, JBW96, and 
JBW97 between 1997 and 2005. The Patient Registry was used to calculate the 
Charlson Co-morbidity Index score for each included patient at the date of surgery.115-
119 The main aim of the study was to determine the risk of recurrence of reflux 
symptoms following antireflux surgery. Two different outcomes were defined as a 
measurement for this: prescribed medication against reflux (PPI or histamine2 receptor 
antagonists) or secondary antireflux surgery (open or laparoscopic). Medical treatment 
was identified using the Anatomical Therapeutical Chemical codes A02BC (PPI) and 
A02BA (histamine2 receptor antagonists). To assess long-term treatment against 
GORD, a cumulative treatment time of more than six months of prescribed 
medications was required. This was calculated using the prescribed amounts of 
defined daily doses, which is defined by the World Health Organisation as “the 
assumed average maintenance dose per day for a drug used for its main indication in 
adults”.120 Further, acute surgical complications were identified in the Patient Registry 
within 30 days of the primary surgery and reported as descriptive data. The 
complications identified were pneumothorax, oesophageal perforation, splenic injury, 
liver injury, and other specifically surgery-associated complications. The Swedish 
Causes of Death Registry was used to censor patients at the date of death as well as to 
identify patients who died within 30 days of primary laparoscopic antireflux surgery. 
4.3.2.3 Statistical methods 
The overall risk of reflux recurrence (requiring reoperation or medication) was 
visualised using Kaplan-Meier analysis. Using multivariable Cox regression the risk 
of recurrence was analysed and presented as hazard ratios with 95% CI. The 
regression models were adjusted for age at surgery (≤45, 46-60 or ≥61 years), sex, 
comorbidity at the date of surgery (Charlson score of 0 or ≥1), calendar year of 
surgery (2005-2006, 2007-2009 or 2010-2014) and total hospital volume during the 
study period (≤24, 25-75 or ≥76). Following the main analyses, a subgroup analysis 
only including individuals without comorbidities under the age of 45 was conducted. 
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4.3.3 Study III 
4.3.3.1 Design 
Systematic review and meta-analysis. 
4.3.3.2 Search strategy and identification of articles 
This study was a systematic review and meta-analysis assessing the available 
literature regarding the potential of preventing oesophageal adenocarcinoma by means 
of antireflux surgery. The systematic review aimed to identify all relevant studies 
assessing the risk of oesophageal adenocarcinoma, comparing antireflux surgery and 
medication due to GORD, as well as comparing antireflux surgery and the risk in the 
background population. The search was restricted until 12th of June 2014. 
PubMed/MedLine database, Web of Science, and Cochrane were searched using the 
following terms: oesophageal, oesophagus, neoplasm, adenocarcinoma, cancer, 
Barrett, fundoplication, antireflux surgery, Nissen, and reflux surgery (taking different 
spellings into consideration). Inclusion criteria were studies that report the incidence 
rates of oesophageal adenocarcinoma in surgically and medically treated patients with 
GORD, or compared surgically treated patients to the background population 
regarding the risk of oesophageal adenocarcinoma. Eligible for inclusion were cohort 
studies, case-control studies, and interventional studies, and no restriction regarding 
language was applied. Backward and forward citation tracking was also conducted to 
identify additional articles. To be included, the studies needed to report data regarding 
the number of cases and the total time of follow-up. 
4.3.3.3 Statistical methods 
Based on the total number of person-years and the number of cases within each group, 
a fixed-effects Poisson meta-analysis was conducted, resulting in pooled incidence 
rate ratios with 95% CI. Two separate meta-analyses were conducted: one comparing 
antireflux surgery with medication against GORD, and one comparing antireflux 
surgery with the risk in the corresponding background population. To determine 
statistical heterogeneity an I2 test was conducted and the results were categorized as 
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low (<50%), moderate (51%-75%) or high (>75%).121 Potential publication bias was 
evaluated by assessing funnel plots. 
4.3.4 Study IV 
4.3.4.1 Design 
Nordic population-based cohort study. 
4.3.4.2 The cohort and the follow-up 
Based on the rapidly increasing incidence of oesophageal adenocarcinoma and the 
potential possibility of preventing oesophageal adenocarcinoma we conducted a 
multi-national cohort study to ensure the power of the analyses. By using the 
nationwide Patient Registries in Denmark, Finland, Iceland, Norway, and Sweden, all 
adult patients with a registered diagnosis of GORD were identified. This cohort was 
named the Nordic Antireflux Surgery Cohort (NordASCo), and details regarding the 
cohort have been published as a cohort profile.122 All patients with GORD who 
underwent antireflux surgery were identified and were compared to patients with 
GORD who did not undergo such surgery, as well as the corresponding background 
population. The outcome was development of oesophageal adenocarcinoma, 
identified in the Cancer Registries, in relation to time after diagnosis or surgery. The 
Causes of Death Registries were used to determine date of death. The Swedish 
Registry of the Total Population was used to determine the incidence of oesophageal 
adenocarcinoma in the corresponding background population. 
4.3.4.3 Statistical methods 
Two statistical approaches were used. First, the risk of developing oesophageal 
adenocarcinoma following antireflux surgery as well as following GORD diagnosis 
was compared to the corresponding background population and standardized 
incidence ratios (SIR) with 95% CI were calculated. The incidence in the background 
population was derived from the Swedish population, and based on the incidence in 
the population of corresponding sex, age, and calendar period. The SIR were 
categorized based on total individual time of follow-up (<5, 5-<10, 10-<15 or ≥15 
years). Second, the risk of oesophageal adenocarcinoma among the operated patients 
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was compared to the risk of oesophageal adenocarcinoma among the non-operated 
patient through Cox regression, calculating hazard ratios and 95% CI. The Cox 
regression models were categorized based on time after surgery or GORD diagnosis 
(<5, 5-<10, 10-<15 or ≥15), and adjustments were made for sex, age at follow-up 
(<50, 50-65 or >65 years), calendar period (-1984, 1985-1999 or 2000-), chronic 
obstructive pulmonary disease, and obesity or diabetes mellitus type 2. To validate the 
use of PPI and histamine2 receptor antagonists among the patients who did not 
undergo antireflux surgery, the Swedish Prescribed Drug Registry was used. Based on 
this registry, the proportion of non-operated patients with GORD as well as severe 
GORD who received prescriptions during the study period was assessed.   
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5 RESULTS 
5.1 STUDY I 
Between 1997 and 2013 a total of 8,947 patients between 18 and 65 years underwent 
primary laparoscopic antireflux surgery in Sweden according to the Patient Registry. 
Main characteristics of the cohort are shown in Table 2.  
Table 2. Main characteristics of the 8,947 patients included in Study I. 
 All patients 
Number (%) 
90-day death 
Number (%) 
90-day reoperation 
Number (%) 
Total 8,947 (100.0) 7 (0.08) 39 (0.4) 
Median age (interquartile range) 48 (38-55) 42 (41-61) 51 (39-56) 
Sex    
   Male 5,306 (59.3) 4 (57.1) 21 (53.9) 
   Female 3,641 (40.7) 3 (42.9) 18 (46.1) 
Charlson comorbidity score*     
   0 8,396 (93.8) 4 (57.1) 35 (89.7) 
   1 488 (5.5) 2 (28.6) 4 (10.3) 
   ≥2 63 (0.7) 1 (14.3) 0 (0.0) 
Median days of stay (interquartile 
range) 
2 (1-3) 11 (3-19) 6 (3-10) 
* A composite variable for quantification of general comorbid status. 
When assessing the number of antireflux surgeries conducted in Sweden, a peak was 
seen around the year 2000 with almost 1,000 surgeries per year, followed by a steady 
decline, and during the last years of study, there were only approximately 150 
antireflux surgeries conducted annually. This is illustrated in Figure 4. The sex 
distribution changed during the study period from approximately 60% male patients, 
to a nearly even distribution. There was an increase in the proportion of patients with 
severe comorbidities who underwent laparoscopic antireflux surgery. In total, there 
were seven deaths (0.08%) within 90 days of surgery. Compared to the entire cohort, 
patients who passed away within 90 days tended to have longer length of hospital-stay 
(Table 2). Age, year of surgery, sex or Charlson co-morbidity was not associated with 
any increased risk of mortality within 90 days of surgery. There were 39 reoperations 
(0.4%) within 90 days of primary surgery, and the reoperated group was similar with 
regards to age and Charlson comorbidity score as the entire cohort (Table 2). Men had 
a lower risk of prolonged hospital stay compared to women (odds ratio 0.76, 95% CI 
0.68-0.86), and higher Charlson comorbidity score was also associated with an 
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increased risk of prolonged hospital stay, both among patients with Charlson 
comorbidity score of 1 (odds ratio 1.36, 95% CI 1.04-1.66) and 2 (odds ratio 2.27, 
95% CI 1.30-4.00). In general, there was a decrease in the odds ratio of prolonged 
hospital stay during the study. This decrease was especially prominent during the first 
years of the study, and a slight increase could be seen from 2005 onwards. 
 
Figure 4. Number of antireflux surgeries conducted in Sweden between 1997 and 2013 in the working 
age population, also the number of patients requiring reoperation within 90 days as well as the 90-
day mortality. 
5.2 STUDY II 
There were 2,655 patients who underwent primary laparoscopic antireflux surgery due 
to GORD in the cohort, and they were followed for a mean of 5.1 years. 
Characteristics of the participating patients are shown in Table 3. Among the included 
patients, 470 (17.7%) had recurrence of reflux, defined as either receiving 
prescriptions of PPI of histamine2 receptor antagonists for more than six months or 
secondary antireflux surgery. Of the patients with reflux recurrence, 393 (83.6%) were 
treated with medication and 77 (16.4%) underwent reoperation. Risk factors for 
recurrence of reflux were female sex, older age, more comorbidities, and more recent 
years of primary surgery, shown in Table 4. Hospital volume of antireflux surgery did 
not influence the risk of reflux recurrence. 
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Table 3. Main characteristics of the patients included in Study II. 
 Entire cohort 
Number (%)  
No recurrence of 
reflux 
Number (%) 
Recurrence of 
reflux 
Number (%) 
Total  2,655 (100.0) 2,185 (100.0) 470 (100.0) 
Recurrence treated with    
   Medication N/A N/A 393 (83.6) 
   Surgery N/A N/A 77 (16.4) 
Sex    
    Male 1,354 (51.0) 1,170 (53.5) 184 (39.1) 
    Female 1,301 (49.0) 1,015 (46.5) 286 (60.9) 
Age     
    ≤45 989 (37.3) 856 (39.2) 133 (28.3) 
    46-60 951 (35.8) 770 (35.2) 181 (38.5) 
    ≥61 715 (26.9) 559 (25.6) 156 (33.2) 
Charlson comorbidity score*    
    0 1,851 (69.7) 1,561 (71.4) 290 (61.7) 
    ≥1 804 (30.3) 624 (28.6) 180 (38.3) 
* A composite variable for quantification of general comorbid status. 
Table 4. Risk factors regarding recurrence of reflux following antireflux surgery. 
 Patients 
Number (%) 
Cases of recurrence 
(% within each row)
Recurrence 
Hazard ratio (95% CI)* 
Sex    
Male 1,354 (51.0) 184 (13.6) 1.00 (Reference) 
Female 1,301 (49.0) 286 (22.0) 1.57 (1.29-1.90) 
Age (years)    
≤45 989 (37.3) 133 (13.4) 1.00 (Reference) 
46-60 951 (35.8) 181 (19.0) 1.28 (1.02-1.61) 
≥61 715 (26.9) 156 (21.8) 1.41 (1.10-1.81) 
Charlson comorbidity 
score** 
   
0 1,851 (69.7) 290 (15.7) 1.00 (Reference) 
≥1 804 (30.3) 180 (22.4) 1.36 (1.13-1.65) 
Year of surgery    
2005-2006 1,098 (41.4) 177 (16.1) 1.00 (Reference) 
2007-2009 802 (30.2) 146 (18.2) 1.61 (1.27-2.03) 
2010-2014 755 (28.4) 147 (19.5) 3.86 (2.98-5.02) 
Hospital volume  
≤24 266 (10.0) 38 (14.3) 1.00 (Reference) 
25-75 863 (32.5) 161 (18.7) 1.13 (0.79-1.62) 
≥76 1,526 (57.5) 271 (17.8) 1.09 (0.77-1.53) 
* Hazard ratio and 95% confidence interval. 
** A composite variable for quantification of general comorbid status. 
In a separate analysis only including 799 patients aged 45 years or younger with no 
co-morbidities, 11.1% of the men and 17.1% of the women had recurrence of reflux. 
Compared to the rest of the population, the risk of recurrence was decreased both 
among men (hazard ratio 0.66, 95% CI 0.49-0.90) and women (hazard ratio 0.67, 95% 
CI 0.48-0.93). In the cohort, 109 (4.1%) had any complication within 30 days of 
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antireflux surgery. The most common complications were infections (1.1%), bleeding 
(0.9%) and oesophageal perforation (0.9%). After primary antireflux surgery, 21 
patients (0.8%) received a diagnosis of dysphagia during the study period, and 14 of 
these patients (0.5%) required endoscopic dilatation. Following secondary antireflux 
surgery, 18 patients (23.4%) suffered from a complication, and the most frequent were 
infection (6.5%), oesophageal perforation (6.5%) and bleeding (5.2%). 
5.3 STUDY III 
Following the systematic search of PubMed/MedLine, Web of Science and Cochrane, 
1,987 studies were considered for inclusion in this systematic review, and among 
these 12 met the inclusion criteria, shown in the search strategy in Figure 5. 
 
Figure 5. Search strategy used in Study III, and number of eligible studies. 
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Ten studies compared an operated to a non-operated group of patients, and these were 
from Ireland, Spain, Sweden, the United Kingdom, and the United States. In total 
there were 100,479 patient-years following antireflux surgery, and 403,459 person-
years among patients with reflux who did not undergo such surgery. The meta-
analysis of these ten studies comparing antireflux surgery with medication found an 
overall incidence rate ratio of 0.89 (95% CI 0.66-1.19; I2 0%), shown in Figure 6. A 
meta-analysis only including patients with a known diagnosis of Barrett’s oesophagus 
indicated a decreased risk of oesophageal adenocarcinoma in the antireflux surgery 
group (incidence rate ratio 0.46 (95% CI 0.20-1.08). In an analysis only including 
patients without Barrett’s oesophagus or with unknown diagnosis the corresponding 
incidence rate ratio was 0.98 (95% CI 0.72-1.33). 
 
Figure 6. Forrest plot comparing the risk of oesophageal adenocarcinoma following antireflux 
surgery to medication, among patients with and without Barrett’s oesophagus, as well as overall. 
Two studies compared the risk of oesophageal adenocarcinoma in patients who 
underwent antireflux surgery to the risk in the general background population, one 
conducted in Finland and one in Sweden. These included 134,438 and 120,514 
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person-years, respectively. The meta-analysis of these studies (Figure 7) found an 
incidence rate ratio of 10.78 (95% CI 8.48-13.71) compared to the general 
background population.   
 
Figure 7. Forrest plot comparing the risk of oesophageal adenocarcinoma following antireflux 
surgery to the general background population. 
5.4 STUDY IV 
In study IV, the entire study cohort included 942,906 patients with GORD in the five 
Nordic countries. Among these, 48,414 patients had undergone antireflux surgery, 
including 30,537 patients with a diagnosis of severe GORD. Some characteristics of 
the study participants are presented in Table 5. Among the patients with GORD who 
did not undergo antireflux surgery, 2,368 patients (0.3%) subsequently developed 
oesophageal adenocarcinoma at a median age of 71 years, and the vast majority of 
these were men (79.6%). Among the patients with severe GORD who did not undergo 
antireflux surgery 1,351 patients (0.5%) later developed oesophageal adenocarcinoma 
at a median age of 70 years, and with an even more pronounced overweight of men 
(83.3%). Among the patients in the overall GORD group who underwent antireflux 
surgery 177 patients (0.4%), of which 86.4% were men, developed oesophageal 
adenocarcinoma during the study period, at a median age of 66 years. Among the 
patients with severe GORD who underwent antireflux surgery, 149 (0.5%) developed 
oesophageal adenocarcinoma, at a median age of 65 years, and among who 85.9% 
were men. Within the group of patients with GORD who did not undergo antireflux 
surgery, the validation analysis found that 92.1% were users of PPI or histamine2 
receptor antagonists. The corresponding figure among patients with severe GORD 
who did not undergo antireflux surgery was 97.3%. 
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Table 5. Main characteristics of the patients included in Study IV. 
Gastro-oesophageal reflux disease 
 No antireflux surgery 
Number (%) 
Antireflux surgery 
Number (%) 
Total    
Patients 894,492 (100) 48,414 (100) 
Person-years of follow-up 6,511,385 (100) 617,181 (100) 
Sex   
Male 434,035 (48.6) 27,161 (56.1) 
Female 459,340 (51.4) 21,253 (43.9) 
Age   
<50 years 291,732 (32.6) 23,825 (49.2) 
50-65 years 267,861 (29.9) 18,206 (37.6) 
>65 years 334,899 (37.4) 6,383 (13.2) 
   
Oesophageal adenocarcinoma 2,368 (0.3) 177 (0.4) 
Median age at diagnosis (interquartile range) 71.0 (62.0-78.0) 66.0 (58.0-73.0) 
   Males 1,884 (79.6) 153 (86.4) 
Females 484 (20.4) 24 (13.6) 
Severe gastro-oesophageal reflux disease 
 No antireflux surgery 
Number (%) 
Antireflux surgery 
Number (%) 
Total    
Patients 264,543 (100) 30,537 (100) 
Person-years of follow-up 2,496,630 (100) 391,908 (100)
Sex    
Male 146,502 (55.4) 17,756 (58.1) 
Female 118,041 (44.6) 12,781 (41.9) 
Age   
<50 years 83,419 (31.5) 15,529 (50.9) 
50-65 years 82,703 (31.3) 11,686 (38.3) 
>65 years 98,421 (37.2) 3,322 (10.9) 
   
Oesophageal adenocarcinoma 1,351 (0.5) 149 (0.5) 
Median age at diagnosis (interquartile range) 70.0 (62.0-77.0) 65.0 (58.0-73.0) 
   Males 1,125 (83.3) 128 (85.9) 
Females 226 (16.7) 21 (14.1) 
The comparison of patients with GORD and severe GORD to the corresponding 
background population are shown in Table 6. Among patients with GORD who 
underwent antireflux surgery, the SIR decreased from 39.19 (95% CI 28.79-52.11) <5 
years after surgery to 1.34 (95% CI 0.98-1.80) ≥15 years after surgery. A similar 
pattern was seen for patients with severe GORD who underwent antireflux surgery, 
although from a higher initial level; the SIR decreased from 72.28 (95% CI 52.08-
97.70) <5 years after surgery to 1.67 (95% CI 1.15-2.35) ≥15 years after surgery. 
Among patients with GORD who did not undergo antireflux surgery (i.e. medically 
treated), the SIR decreased from 17.71 (95% CI 16.88-18.56) <5 years after inclusion 
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to 0.69 (95% CI 0.59-0.81) ≥15 years after inclusion. Among patients with severe 
GORD who did not undergo antireflux surgery, the SIR decreased from 37.65 (95% 
CI 35.20-40.22) <5 years after inclusion to 1.16 (95% CI 0.97-1.39) ≥15 years after 
inclusion. 
Table 6. Risk of oesophageal adenocarcinoma (OAC) among patients with gastro-oesophageal reflux 
disease (GORD) and severe GORD following antireflux surgery or not, compared to the 
corresponding background population. 
Gastro-oesophageal reflux disease 
 No antireflux surgery Antireflux surgery 
 Patients OAC SIR (95% CI)* Patients OAC SIR (95% CI)* 
Follow-up 
(years)       
 <5 438,096 1,717 17.71 (16.88-18.56) 7,376 47 39.19 (28.79-52.11) 
5-<10 223,842 310 2.06 (1.83-2.30) 10,068 39 7.63 (5.42-10.43) 
10-<15 127,960 185 1.31 (1.12-1.51) 13,428 46 3.64 (2.66-4.85) 
≥15 104,594 156 0.69 (0.59-0.81) 17,542 45 1.34 (0.98-1.80) 
Severe gastro-oesophageal reflux disease 
 No antireflux surgery Antireflux surgery 
 Patients OAC SIR (95% CI)* Patients OAC SIR (95% CI)* 
Follow-up 
(years)       
<5 94,840 882 37.65 (35.20-40.22) 3,546 42 72.28 (52.08-97.70) 
5-<10 70,790 216 3.90 (3.40-4.45) 6,632 34 10.08 (6.98-14.09) 
10-<15 50,475 130 2.02 (1.68-2.39) 9,494 40 4.47 (3.20-6.09) 
≥15 48,351 123 1.16 (0.97-1.39) 10,865 33 1.67 (1.15-2.35) 
* Standardised incidence ratio and 95% confidence interval 
The analysis comparing patients with GORD who had undergone antireflux surgery to 
patients with GORD who had not undergone such surgery is presented in Table 7. 
Compared to patients with GORD who did not undergo antireflux surgery, patients 
who underwent such surgery were at a stable elevated risk of oesophageal 
adenocarcinoma <5 years and ≥15 years after surgery (hazard ratio 1.86, 95% CI 1.39-
2.49, and 1.80, 95% CI 1.28-2.54, respectively). In the group with severe GORD, the 
hazard ratio also remained stable, but elevated, among the patients who underwent 
surgery compared to the patients who did not undergo such surgery, with a hazard 
ratio of 1.62 (95% CI 1.18-2.22) <5 years after surgery and 1.69 (95% CI 1.14-2.51) 
≥15 years after surgery. 
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Table 7. The risk of oesophageal adenocarcinoma (OAC) among patients with GORD and severe 
GORD comparing patients who have underwent antireflux surgery or not. 
Gastro-oesophageal reflux disease 
 No antireflux surgery Antireflux surgery 
 Total OAC 
Hazard ratio 
(95% CI)* Total OAC 
Hazard ratio (95% 
CI)* 
Follow-up 
(years)       
<5 438,096 1,717 1.00 (Reference) 7,376 47 1.86 (1.39-2.49) 
5-<10 223,842 310 1.00 (Reference) 10,068 39 2.02 (1.44-2.84) 
10-<15 127,960 185 1.00 (Reference) 13,428 46 1.96 (1.41-2.74) 
≥15 104,594 156 1.00 (Reference) 17,542 45 1.80 (1.28-2.54)
Severe gastro-oesophageal reflux disease 
 No antireflux surgery Antireflux surgery 
 Total OAC 
Hazard ratio 
(95% CI)* Total OAC 
Hazard ratio (95% 
CI)* 
Follow-up 
(years)       
<5 94,840 882 1.00 (Reference) 3,546 42 1.62 (1.18-2.22) 
5-<10 70,790 216 1.00 (Reference) 6,632 34 1.81 (1.24-2.63) 
10-<15 50,475 130 1.00 (Reference) 9,494 40 1.71 (1.18-2.49) 
≥15 48,351 123 1.00 (Reference) 10,865 33 1.69 (1.14-2.51)
* Hazard ratio and 95% confidence interval 
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6 METHODOLOGICAL CONSIDERATIONS 
In the current thesis, three of the studies are cohort studies and one is a systematic 
review and meta-analysis. These designs have different methodological challenges. 
6.1 COHORT STUDIES 
Study I, II, and IV are population-based cohort studies. Two (Study I and II) were 
nationwide Swedish studies and one (Study IV) included nationwide data from all five 
Nordic countries. A cohort study consists of a designated group of individuals with 
information about one or more pre-specified exposures who are followed up over a 
period of time for one or more outcomes of interest.123 Due to the similarities in study 
design in studies I, II, and IV they share some methodological aspects. A major 
strength is the population-based design, including virtually all patients in Sweden or 
the Nordic countries who fulfil the inclusion criteria and with complete follow-up in 
the registries. This design counteracts selection bias and loss to follow-up. The 
nationwide inclusion also enabled large sample sizes, which allowed the study of the 
rare outcome oesophageal adenocarcinoma with sufficient power. Based on the 
richness of data in the included registries, it is also possible to adjust the results for 
potential confounding factors. Among weaknesses with observational study designs in 
general is the risk of different types of systematic errors (bias), which might affect the 
validity of the study. There are three types of bias that might affect an observational 
study: selection bias, information bias, and confounding. The ambition when 
designing any observational study is to reduce such biases, thereby reducing the 
systematic errors.  
Selection bias constitutes a systematic non-random error in the selection and inclusion 
of individuals in the study which might result in the studied cohort not reflecting the 
population that is intended to be analysed.123 Since all cohort studies included in this 
thesis are population-based, virtually including all patients within each country, 
selection bias should not be affected due to lack of participation. However, there is a 
risk that the definitions regarding the inclusion criteria might affect the participation. 
Further, there is a risk that local traditions within different hospitals or clinics might 
influence the diagnoses that patients receive. This might for example influence what 
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patients receive a diagnosis of heartburn or not in a clinical practice if this is not the 
main reason for the patient seeking medical care.  
Information bias is a “flaw in measuring exposure, covariate, or outcome variables 
that results in different quality of information between comparison groups”.124 It can 
be categorized as differential (non-random) when the misclassification differs between 
the comparison groups or non-differential (random) when the misclassification does 
not differ between the groups. Non-differential misclassification is often considered to 
lead to an underestimation of associations. In the current studies, misclassification 
should not be a major issue if the validity of the codes that are used is high. Since 
diagnostic and surgical codes often are directly associated to monetary reimbursement 
for the clinics, the validity of these is generally high. The cancer diagnoses are often 
reported centrally directly from the pathologists or oncological clinics, which also 
results in a high reliability of the coding. In study II, medications in the Prescribed 
Drug Registry were used as a proxy for recurrence of GORD, however it is impossible 
to know the compliance, i.e. whether the patients actually took their medication or not, 
based on this data. To avoid bias due to this, we decided to only include patients who 
received prescriptions accounting for at least six months of medication. 
Confounding constitutes a challenge in most observational research. A confounder is 
defined as a factor which is associated both with the exposure and outcome, without 
being in the causal pathway between these two. In the studies included in this thesis, 
mainly multivariable regression was used to handle confounding. Although 
confounding was attempted to be handled within each study there is always a risk of 
residual confounding of unknown factors and rough categorisation of factors adjusted 
for, which might affect the analyses. This might also be caused by low registration of 
factors that are considered confounders or a lack of a good enough proxy that might 
reflect such confounding. 
Random error is the variation of test results when repeated. These random errors 
might be present in any study. However, depending mainly on sample size, the level 
of precision can be increased, thereby resulting in more reliable results. Any analysis 
results in a point estimate, but to give a measurement of the precision of the analysis 
these are often presented with 95% confidence intervals or a p-value. The confidence 
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interval reflects within which interval a certain proportion of the measurements (e.g. 
95%) would fall in if the measurements were conducted numerous times (and was free 
from bias). Another common measurement which indirectly reflects the precision is 
the p-value. P-value is a measurement of the probability that the null hypothesis is 
true, meaning that there is no association between the exposure and the outcome. 
Therefore, a low p-value would indicate evidence against the null hypothesis, 
meaning that the alternative hypothesis is true, suggesting a true difference between 
the two groups that are compared. In clinical studies 95% confidence intervals are 
often more informative by not only providing information regarding statistical 
significance, but also regarding direction and strength of the effect.125 
6.2 SYSTEMATIC REVIEW AND META-ANALYSIS 
Study III is a systematic review and meta-analysis. Based on a systematic search in 
three of the major databases for scientific literature (PubMed/MedLine database, Web 
of Science, and Cochrane) relevant articles were identified. Following this, data were 
extracted and analysed in a meta-analysis. Meta-analysis can be a powerful tool to 
summarize large amounts of data, and reach new, more reliable conclusions. There are 
however many challenges with this approach as well. Except for the potential biases 
involved in each of the included studies, there are specific issues related to meta-
analyses: publication bias, search bias, selection bias and heterogeneity.  
Publication bias represents one of the major issues both in meta-analyses and in the 
medical literature in general. This represents the issue that positive results of statistical 
significance and results with a larger “media impact” are more likely to be published 
and to be published more rapidly than negative or inconclusive results.126,127 This bias 
will directly affect the data available for inclusion in a meta-analysis. Due to the 
nature of the issue where many studies are initiated without being centrally registered 
or followed up, it is hard to assess how large the issue is. One method of determining 
whether publication bias exists is to conduct a funnel plot. A funnel plot is a 
scatterplot with the treatment effect on the x-axis and the standard error (study 
precision or random error) on the y-axis, thereby large studies will appear at the top of 
the funnel with smaller studies at the bottom. The dotted lines represent the assumed 
95% confidence interval around the treatment effect and an asymmetrical distribution 
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indicates publication bias. The funnel plot of the main analysis in study IV is 
presented in Figure 8. In the current meta-analysis, the overall assessment is that no 
significant publication bias exists, although there is a slight skewness among the 
smallest studies. 
 
 
Figure 8. Funnel plot of the included articles in study IV comparing patients undergoing surgery to 
patients receiving medical treatment. 
Search bias represents the issues that can arise from a skewed or incomplete search. 
This can either be due to the selection of keywords used or the selection of databases 
to search. If the search strategy is too narrow or incomplete, important studies might 
be missed, thereby resulting in a bias in the meta-analysis.  
Selection bias in a meta-analysis may occur during the selection and inclusion of 
studies following the search. To ensure that the selection takes place in a controlled 
and reproducible way, inclusion criteria need to be determined beforehand and strictly 
followed. These criteria should state what type of study designs that will be included, 
what kind of outcome measurements are necessary, et cetera. This was done in study 
III.  
Statistical heterogeneity is a measurement of the variation in the studies, which helps 
determine if the studies are similar enough to be combined in a meta-analysis. One 
method of determining statistical heterogeneity is by calculating I2 which measures 
the percentage of variance that can be attributed to study heterogeneity, which was 
used in the current meta-analysis. If the heterogeneity is determined to be low, a fixed 
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effects meta-analysis can be conducted, in which each of the included studies are 
assumed to estimate the same underlying parameter, and that the different estimates 
between the studies are only due to random error. If the heterogeneity is found to be 
large, this can be handled using a random effects meta-analysis, which assumes that 
the effects studied are not identical, both due to heterogeneity between the studies and 
due to random error within each study.  
Clinical heterogeneity can also affect the conduction and interpretation of a meta-
analysis. If the included studies are conducted in very different clinical settings, where 
for example the indication for treatment, type of treatment, follow-up, and duration of 
treatment are very different, the clinical heterogeneity might affect the reliability and 
possibility to interpret the results of the meta-analysis. 
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7 GENERAL DISCUSSION 
7.1 STUDY I  
Study I found very low mortality and reoperation rates among adults of working age 
who underwent primary laparoscopic antireflux surgery. The trend in the number of 
surgeries showed a clear peak around the turn of the millennium, followed by a steady 
decrease. The proportion of patients with severe comorbidities who underwent 
laparoscopic antireflux surgery increased during the later years.  
Strengths in the study are the complete coverage of the registries as well as the 
complete follow-up of the patients. Among weaknesses is the risk that patients who 
are selected for surgery might be healthier compared to the general population. 
However, such selection bias still reflects clinical practice due to the population-based 
methodology. There is also a risk of confounding due to potential confounders such as 
tobacco smoking, which might affect the outcomes. 
Due to the low risk of mortality and reoperation, laparoscopic antireflux surgery can 
be considered a safe procedure, with a risk similar to other operations for benign 
conditions. The initial increase in the number of surgeries might both be attributable 
to an increased detailed coding following the implementation of the NOMESCO as 
well as an actual increase in the number of procedures. The shown decrease in the 
number of surgeries can be attributed to a few different factors. The introduction and 
increased availability and use of PPI during the late 20th century had a large impact on 
the pharmacological treatment options for GORD.128 Since PPI generally offer good 
symptom relief for most patients, this is indeed the main treatment option. Further, the 
potential risks of surgical complications and mortality might have affected clinicians’ 
willingness to refer patients to surgery, especially in relation to the safer and effective 
pharmacological treatment option, and similar patterns in the use of surgery have been 
shown in previous studies.129 Some recent studies have however raised the question 
regarding side-effects due to long-term treatment with PPI.34-37 There is also a matter 
of availability of surgery and monetary reimbursement, which can affect the 
possibility to undergo antireflux surgery. The aspect of cost-effectiveness was not 
assessed in the current study. However surgery might be a more cost-effective 
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treatment option in the long-term setting, making it an appealing treatment option 
especially for young patients.54 
The study also found an increased risk of prolonged hospital stay associated with 
more comorbidities and higher age. This might be due to a higher risk of 
complications as well as a slower recovery following surgery.  
Overall, laparoscopic antireflux surgery can be considered a safe treatment option for 
GORD. 
7.2 STUDY II  
In study II we found that among adult patients undergoing primary laparoscopic 
antireflux surgery, 17.7% had recurrence of reflux, defined as either undergoing 
reoperation or receiving medical treatment (PPI or histamine2 receptor antagonists) for 
more than six months. Higher risk of recurrence was associated with female sex, older 
age, and comorbidities. The number of surgeries performed at the hospital was not 
associated with increased risk of recurrence. The lowest risk of recurrence was found 
among young and otherwise healthy men, and in a sub-analysis of patients below 45 
years of age and without comorbidities we found a recurrence rate of 11.1% among 
men. The overall risk of recurrence in the study is lower than most previously 
published cohort studies on the topic,130-135 and the proportion of patients undergoing 
reoperation was also lower than previous studies.49,50 
Among the strengths of the current study is the nationwide and complete coverage. 
Further, the combined outcome, both including reoperation and long-term medication 
reliably identifies patients with recurrence. Some of the weaknesses is the use of PPI 
bought over the counter which is not included in the registry and whether or not 
patient compliance was sufficient. Clinical practice might also vary between clinics, 
inducing an uncertainty in the coding. Further, as in any observational study, the risk 
of confounding is a challenge in the current study. 
The explanation for the findings might be attributed both to the study design, patient 
selection, as well as biological aspects. The study design was a nationwide study with 
complete follow-up and a larger cohort compared to most previously published cohort 
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studies. Further, due to the increasing use of medication against GORD and 
decreasing use of surgery over the last decades, the selection of patients might be 
stricter and the surgical quality at the centres that conduct the surgeries might be 
higher. However, there is a risk that patients who are eventually selected for surgery 
suffer from more severe GORD with incomplete relief of symptoms following 
medication. Considering this, the rate of recurrence in the study might be considered 
to be low. Some previous studies have shown that women might experience more 
severe symptoms of GORD despite having an objectively similar grade of GORD as 
men.136 Age and comorbidities might be associated with a higher risk of recurrence 
due to a more severe and refractory type of GORD, which might be at a higher risk of 
recurrence.  
The study also assessed complications within 30 days of primary and secondary 
antireflux surgery and showed a complication rate of 4.1% and 23.4%, respectively. 
The most common complications were infection, bleeding and oesophageal 
perforation. Previous studies have found low, albeit higher than ours, risk of 
complications. The higher risk of complications associated with secondary surgery 
compared to primary surgery is in line with previously published data, further 
highlighting the risk of complications following reoperation.137,138 
In conclusion, the risk of recurrence following laparoscopic antireflux surgery is 
relatively low, particularly in young men, as is the risk for complications following 
the procedure. Therefore, antireflux surgery might be an underused treatment option. 
7.3 STUDY III  
The systematic review and meta-analysis in study III did not find a more preventive 
effect against the development of oesophageal adenocarcinoma following antireflux 
surgery compared to antireflux medication in the overall analysis. However, there was 
a lower point estimate in favour of surgery in the meta-analysis only including 
patients with Barrett’s oesophagus compared to the analysis only including patients 
without confirmed Barrett’s oesophagus. In the analysis comparing antireflux surgery 
to the general background population, the risk of oesophageal adenocarcinoma 
remained highly elevated over time following surgery. 
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One limitation of a meta-analysis is the weaknesses associated with the individual 
studies. For example, none of the included studies differentiated between duration of 
GORD and symptom severity (although the diagnosis of Barrett’s oesophagus was 
included in some studies). Further, no analysis was based on the duration of treatment, 
i.e. time after surgery or initiation of medication. There is also a risk of search and 
selection bias. Similar to any meta-analysis, there is also a risk of publication bias (the 
file drawer problem) meaning that non-significant or negative results might not have 
been published in the first place, making such studies impossible to identify and 
include in the analysis. 
In conclusion, this study did not find any significant difference between antireflux 
surgery and medication regarding prevention of oesophageal adenocarcinoma. There 
was, however, a lower point estimate favouring surgery among patients with Barrett’s 
oesophagus. This could indicate that patients with Barrett’s oesophagus might benefit 
more from antireflux surgery, although the data available is not sufficient to establish 
this.  
7.4 STUDY IV  
This nationwide Nordic study found a decreasing risk of developing oesophageal 
adenocarcinoma compared to that of the general background population over time, 
both among patients undergoing surgery and patients assumed to receive medical 
treatment. When comparing these two groups, no trend was seen over time, and the 
patients who underwent surgery remained at a constant, slightly elevated level. 
Strengths include the population-based design, reflecting clinical practice and 
facilitating generalisability, and large cohort size, increasing the statistical power. The 
separate analyses of overall GORD as well as severe GORD enabled a valuable 
comparison between these two groups. Among the weaknesses were the risk of 
residual confounding and incomplete data regarding medical consumption in the 
groups. 
Previous studies have not found any preventive effect following antireflux surgery 
compared to the background population, both separately and when combined in a 
meta-analysis (Study III).139-141 This might be attributable to earlier studies only 
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including few cases, with a small number of patients included in the longer follow-up 
categories. In the current study, there was no change in risk over time comparing the 
surgically treated and presumed medically treated patients. However, patients who 
underwent surgery were generally at a higher risk of oesophageal adenocarcinoma. 
This could be due to patients undergoing surgery might have had more severe GORD 
with longer duration before initiation of treatment.142  
In conclusion, effective treatment of GORD with surgery or medication seems to 
decrease the risk of developing oesophageal adenocarcinoma over time, with a risk on 
the same level as the background population more than 15 years after surgery or 
diagnosis. Medical and surgical treatment seems to follow the same pattern of 
decreasing risk of oesophageal adenocarcinoma over time. 
7.5 CLINICAL IMPLEMENTATIONS 
In a clinical setting, this thesis concludes that laparoscopic antireflux surgery can be 
considered a safe procedure with low postoperative mortality and few complications. 
Laparoscopic antireflux surgery is also associated with a short postoperative hospital 
stay and a low risk of recurrence of reflux, especially among young and healthy 
individuals. Previous studies have found that both overall health-related quality of life 
as well as the GORD-specific quality of life is improved following antireflux surgery, 
comparing patients undergoing surgery and receiving medical treatment.43 There are 
also studies indicating that surgical treatment of GORD might be more cost-effective 
than medication, especially in a long-term setting compared to medical 
treatment.43,143,144 
Medication, on the other hand, is easily available, both over the counter and on 
prescription, and it carries few direct side effects. However, some studies have raised 
concerns that long-term treatment with PPI might lead to adverse events, such as hip 
fracture, Clostridium difficile-associated diarrhoea, and community-acquired 
pneumonia.34-37 Further, recent studies have also raised concerns regarding long-term 
medication using PPI and risk of gastric cancer.38,39 
The thesis also showed that effective treatment against GORD can reduce the risk of 
developing oesophageal adenocarcinoma over time, with a risk at the same level as 
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the background population after more than 15 years. In all, this would mean that a 
low-risk procedure, with low mortality and morbidity, could decrease the risk of 
developing a highly lethal cancer with poor outcome and increasing incidence. In 
parallel with this, the number of individuals undergoing laparoscopic antireflux 
surgery has drastically decreased, reaching its lowest levels during the last few years.  
In summary, first-line treatment of GORD should continue to be medication with PPI. 
However, surgical treatment against GORD using laparoscopic antireflux surgery is 
likely an underused treatment option in clinical practice today and should remain in 
the clinical arsenal. Surgery should especially be considered among young and 
healthy individuals with severe GORD, who otherwise would require long-term 
medical treatment for a potentially life-long period of time.  
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8 CONCLUSIONS 
 The short-term postoperative risks associated with laparoscopic antireflux 
surgery are low, regarding both complications and mortality. 
 The rate of recurrence of reflux following antireflux surgery is rather low in a 
long-term setting, particularly in younger and otherwise healthy men. 
 Effective treatment with surgery or medication against GORD seems to 
prevent oesophageal adenocarcinoma; antireflux surgery and medication are 
seemingly similarly effective in this respect. 
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9 FUTURE RESEARCH 
GORD is common in the western population with an increasing incidence. Regarding 
the use of laparoscopic antireflux surgery as a treatment of GORD, future research 
should focus on identifying which patients should be recommended such surgery, 
both in relation to associated risks and clinical relieve of reflux symptoms. Further, 
future research should aim at determining whether the presence of Barrett’s 
oesophagus influences what treatment is most beneficial and should be recommended. 
Another aspect is to clarify which treatment is most cost-effective in a long-term 
clinical setting, and whether this might affect the choice of treatment. From a 
pharmacological perspective, large population-based studies should also aim at further 
determining the potential long-term side effects of PPI, and further elucidate how to 
handle patients requiring long-term medical treatment.  
Future research should also aim at the oncopreventive aspects following antireflux 
surgery, especially regarding oesophageal adenocarcinoma. This thesis provides some 
evidence of an oncopreventive effect following treatment of GORD, but this needs to 
be established in further research and due to the low incidence of oesophageal 
adenocarcinoma large studies with long duration of follow-up are needed. Further, 
GORD has been indicated to be associated with some extra-oesophageal cancers, such 
as laryngeal and pharyngeal cancers, and these should also be studied in relation to 
antireflux surgery. 
  
  45 
10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
10.1 BAKGRUND 
Gastroesofageal refluxsjukdom orsakas av läckage av surt maginnehåll förbi den övre 
magmunnen och upp i matstrupen, vilket leder till halsbränna och/eller sura 
uppstötningar. Det uppskattas att 10-20% av den vuxna befolkningen lider av 
gastroesofageal refluxsjukdom, och denna siffra har ökat senaste decennierna. 
Långvarig gastroesofageal refluxsjukdom kan leda till inflammation i matstrupen 
(esofagit), cellförändringar i matstrupen (Barretts esofagus), men även 
matstrupscancer (esofagusadenocarcinom). Matstrupscancer är en cancer som ökar i 
västvärlden och är associerad med krävande behandling, men har trots det en dyster 
prognos. Gastroesofageal refluxsjukdom kan antingen behandlas med läkemedel, och 
då framförallt protonpumpshämmare som verkar genom att minska syraproduktionen i 
magsäcken och därmed symtomen, eller kirurgiskt med antirefluxkirurgi. Vid 
antirefluxkirurgi förs en del av magsäcken runt matstrupen och sys ihop på framsidan, 
vilket leder till att den övre magmunnen snävas åt vilket mekaniskt hindrar 
maginnehållet från att nå matstrupen.  
Denna avhandling syftar till att klargöra riskerna vid antirefluxkirurgi, förtydliga 
risken att återfå symtom av reflux efter antirefluxkirurgi, samt utreda möjligheten att 
förhindra matstrupscancer genom effektiv behandling av gastroesofageal 
refluxsjukdom. 
10.2 METODER OCH RESULTAT 
Tidigare studier har visat att risken för allvarliga komplikationer och död i samband 
med antirefluxkirurgi med titthålsteknik varit relativt hög, och likaså risken att 
patienterna ska få tillbaka sina refluxbesvär efter operationen.  
Syftet med Studie I var att kartlägga risken för död, behov av en akut omoperation, 
samt risken för förlängd sjukhusvistelse efter antirefluxkirurgi hos patienter mellan 18 
och 65 års ålder. Patienterna identifierades i patientregistret och följdes upp i både 
Patientregistret samt Dödsorsaksregistret, Populationsregistret användes för att 
beräkna trender avseende antirefluxkirurgi. Studieperioden var från 1997 till 2013. 
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Multivariabel logistisk regressionsanalys justerat för ålder, kön, år för operation, och 
samsjuklighet användes för att identifiera riskfaktorer för omoperation eller förlängd 
sjukhusvistelse. Totalt inkluderades 8 947 patienter i studien. Studien fann en mycket 
låg risk för död (0,08%) och omoperation (0,4%) inom 90 dagar efter antirefluxkirurgi 
som utförts med titthålsteknik. Vidare visade studien att antalet operationer som utförs 
i Sverige radikalt minskade under studietiden, från 15,3 per 100 000 invånare 1997 till 
2,4 per 100 000 invånare 2013. Under samma period observerades att andelen 
patienter med tung samsjuklighet ökat, men denna ökning i samsjuklighet åtföljdes 
dock inte av någon ökning i dödlighet eller omoperation.  
Syftet med Studie II var att undersöka hur stor andel av patienterna som fick tillbaka 
sina refluxbesvär bland de vuxna patienter som genomgått antirefluxkirurgi med 
titthålsteknik. Studien var en kohortstudie mellan åren 2005 och 2014, och patienterna 
identifierades i Patientregistret, vilket länkades till Dödsorsaksregistret samt 
Läkemedelsregistret. Som mått på återfall av refluxbesvär användes antingen 
operation med förnyad antirefluxkirurgi eller medicinsk behandling av 
gastroesofageal refluxsjukdom som patienten erhållit recept på och vilken översteg 
sex månaders behandlingstid. Multivariabel Cox regression justerat för ålder, kön, år 
för operationen, samsjuklighet, samt antalet operationer som utförts på sjukhuset 
användes för att identifiera riskfaktorer för att patienten skulle återfå 
behandlingskrävande refluxbesvär efter operation. Vidare undersöktes risken att 
drabbas av komplikationer i samband med den primära operationen eller en eventuell 
omoperation. Totalt inkluderades 2 655 patienter, och dessa följdes under 5,1 års tid 
(medelvärde). Av patienterna drabbades 17,7% av behandlingskrävande refluxbesvär 
efter antirefluxkirurgi, som antingen behandlades medicinskt eller kirurgiskt. 
Majoriteten av dessa (83,6%) behandlades med läkemedel. Riskfaktorer för att återfå 
besvär efter antirefluxoperation var kvinnligt kön, högre ålder, samsjuklighet, samt 
senare operationsår, men risken var särskilt låg hos unga och i övrigt friska män. 
Något samband mellan antalet operationer och risken att återfå behandlingskrävande 
refluxbesvär kunde inte ses. Bland de som genomgick antirefluxkirurgi med 
titthålsteknik drabbades 4,1% av en komplikation inom 30 dagar efter operationen, 
motsvarande siffra vid omoperation var 23,4%. De vanligaste komplikationerna var 
infektion, blödning, och skador på matstrupen.  
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Syftet med Studie III var att identifiera publicerade artiklar som utvärderat 
möjligheten att förhindra utvecklingen av matstrupscancer genom behandling av 
gastroesofageal refluxsjukdom, och genom en meta-analys väga samman dessa 
resultat. Tre stora internationella databaser söktes igenom, och totalt identifierades 12 
artiklar som antingen jämförde kirurgisk och medicinsk behandling, eller kirurgisk 
behandling med bakgrundbefolkningen. Tio studier jämförde medicinsk och kirurgisk 
behandling, och vid sammanvägd analys av dessa kunde ingen skillnad mellan 
medicinsk och kirurgisk behandling påvisas. Vid separata analyser mellan de studier 
som bara inkluderade patienter med Barretts esofagus och de som inte gjorde detta 
sågs en antytt mer skyddande effekt av kirurgi, även om någon statistiskt säkerställd 
skillnad inte gick att påvisa. Två studier jämförde risken för matstrupscancer efter 
antirefluxoperation med risken hos bakgrundsbefolkningen. I denna analys påvisades 
en fortsatt förhöjd risk för matstrupscancer efter operation jämfört med 
bakgrundsbefolkningen.  
Syftet med Studie IV var att undersöka om antirefluxkirurgi kan förhindra 
uppkomsten av matstrupscancer. Genom ett nordiskt samarbete sammanställdes en 
databas baserat på nationella register avseende patienter med gastroesofageal 
refluxsjukdom. Data samlades in från Patientregistret, Cancerregistret, samt 
Dödsorsaksregistret i de fem nordiska länderna (Danmark, Finland, Island, Norge, och 
Sverige), samt det svenska Läkemedelsregistret. Studieperioden sträckte sig mellan 
1964 och 2014, med variationer mellan länderna baserat på när registren grundades. 
Risken för cancer jämfördes dels med bakgrundsbefolkningen genom beräkning av 
stardardiserad incidensratio, justerat för ålder, kön, och kalenderperiod. Vidare 
jämfördes patienter som genomgått antirefluxkirurgi med ickeopererade patienter 
(förmodat medicinskt behandlade) genom multivariabel Cox regression justerat för 
ålder, kön, kalenderperiod, KOL (som ett mått på rökning) samt övervikt. Alla vuxna 
patienter med gastroesofageal refluxsjukdom inkluderades i studien, och totalt 
inkluderades 942 906 patienter varav 48 414 genomgått antirefluxkirurgi. Risken för 
att utveckla matstrupscancer var initialt kraftigt förhöjd både bland patienter som 
genomgick antirefluxkirurgi och de som inte genomgick operation (medicinskt 
behandlade), men efter mer än 15 år hade risken minskat och låg därefter på samma 
nivå som bakgrundbefolkningen. När medicinsk och kirurgisk behandling jämfördes 
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med varandra sågs liknande minskad risk för att utveckla matstrupscancer vid bägge 
behandlingarna. 
10.3 SLUTSATS 
Kirurgisk behandling av halsbränna genom antirefluxkirurgi med titthålsteknik 
förknippas med mycket låg risk för allvarliga komplikationer och död. Risken för att 
återfå sin halsbränna efter operation får betraktas som låg, och är särskilt låg hos unga 
och i övrigt friska män. Effektiv behandling av halsbränna, såväl medicinsk som 
kirurgisk, minskar risken att utveckla cancer i matstrupen, och efter mer än 15 år 
ligger risken för matstrupscancer på samma nivå som hos bakgrundsbefolkningen. 
Dock har användandet av kirurgisk behandling av halsbränna minskat de senaste två 
decennierna, till förmån för medicinsk behandling. 
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